Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Different schedules of granulocyte growth factor support for patients with breast cancer receiving adjuvant dose-dense chemotherapy: a prospective nonrandomized study.

Hendler D, Rizel S, Yerushalmi R, Neiman V, Bonilla L, Braunstein R, Sulkes A, Stemmer SM.

Am J Clin Oncol. 2011 Dec;34(6):619-24. doi: 10.1097/COC.0b013e3181f94716.

PMID:
21217400
2.

Granulocyte-colony stimulating factor use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer.

Griffiths RI, Barron RL, Gleeson ML, Danese MD, O'Hagan A, Chia VM, Legg JC, Lyman GH.

Pharmacoeconomics. 2012 Feb 1;30(2):103-18. doi: 10.2165/11589440-000000000-00000.

PMID:
21967155
3.

Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case-control study of the Hellenic Cooperative Oncology Group.

Skarlos DV, Timotheadou E, Galani E, Samantas E, Grimani I, Lianos E, Aravantinos G, Xanthakis I, Pentheroudakis G, Pectasides D, Fountzilas G.

Oncology. 2009;77(2):107-12. doi: 10.1159/000229504. Epub 2009 Jul 21.

PMID:
19622901
4.

Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide.

Papaldo P, Lopez M, Marolla P, Cortesi E, Antimi M, Terzoli E, Vici P, Barone C, Ferretti G, Di Cosimo S, Carlini P, Nisticò C, Conti F, Di Lauro L, Botti C, Di Filippo F, Fabi A, Giannarelli D, Calabresi F.

J Clin Oncol. 2005 Oct 1;23(28):6908-18. Epub 2005 Aug 29.

5.

Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial.

García-Carbonero R, Mayordomo JI, Tornamira MV, López-Brea M, Rueda A, Guillem V, Arcediano A, Yubero A, Ribera F, Gómez C, Trés A, Pérez-Gracia JL, Lumbreras C, Hornedo J, Cortés-Funes H, Paz-Ares L.

J Natl Cancer Inst. 2001 Jan 3;93(1):31-8.

6.

Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensity.

Ribas A, Albanell J, Bellmunt J, Solé-Calvo LA, Bermejo B, Gallardo E, Vidal R, Vera R, Eres N, Carulla J, Baselga J.

J Clin Oncol. 1996 May;14(5):1573-80.

PMID:
8622074
7.

Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors.

Mayordomo JI, Rivera F, Díaz-Puente MT, Lianes P, Colomer R, López-Brea M, López E, Paz-Ares L, Hitt R, García-Ribas I, et al.

J Natl Cancer Inst. 1995 Jun 7;87(11):803-8.

PMID:
7540696
9.

Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain--results of the LEARN Study.

Almenar D, Mayans J, Juan O, Bueno JM, Lopez JI, Frau A, Guinot M, Cerezuela P, Buscalla EG, Gasquet JA, Sanchez J.

Eur J Cancer Care (Engl). 2009 May;18(3):280-6. doi: 10.1111/j.1365-2354.2008.00959.x. Epub 2008 Dec 8.

10.

A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.

Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, Siena S, Lalisang RI, Samonigg H, Clemens MR, Zani V, Liang BC, Renwick J, Piccart MJ; International Pegfilgrastim 749 Study Group.

Ann Oncol. 2003 Jan;14(1):29-35.

11.

Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer.

Jones SE, Schottstaedt MW, Duncan LA, Kirby RL, Good RH, Mennel RG, George TK, Snyder DA, Watkins DL, Denham CA, Hoyes FA, Rubin AS.

J Clin Oncol. 1996 Nov;14(11):2976-83.

PMID:
8918495
12.

The role of granulocyte colony-stimulating factor (filgrastim) in maintaining dose intensity during conventional-dose chemotherapy with ABVD in Hodgkin's disease.

Silvestri F, Fanin R, Velisig M, Barillari G, Virgolini L, Zaja F, Russo D, Baccarani M.

Tumori. 1994 Dec 31;80(6):453-8.

PMID:
7534963
13.

CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients.

Todisco E, Castagna L, Sarina B, Mazza R, Magagnoli M, Balzarotti M, Nozza A, Siracusano L, Timofeeva I, Anastasia A, Demarco M, Santoro A.

Eur J Haematol. 2007 Feb;78(2):111-6.

PMID:
17313558
14.
15.

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.

Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C; European Organisation for Research and Treatment of Cancer.

Eur J Cancer. 2011 Jan;47(1):8-32. doi: 10.1016/j.ejca.2010.10.013. Epub 2010 Nov 20.

PMID:
21095116
16.

Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia.

Heaney ML, Toy EL, Vekeman F, Laliberté F, Dority BL, Perlman D, Barghout V, Duh MS.

Cancer. 2009 Oct 15;115(20):4839-48. doi: 10.1002/cncr.24535.

18.

Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.

Miller AA, Hargis JB, Lilenbaum RC, Fields SZ, Rosner GL, Schilsky RL.

J Clin Oncol. 1994 Dec;12(12):2743-50.

PMID:
7527456
Items per page

Supplemental Content

Write to the Help Desk